Sunho Biologics Inc (2898.HK) Q2 2025 Earnings Report

Sunho Biologics Inc. reported QQ2 2025 results with a clearly pre-revenue economic profile typical of a clinical-stage biopharma company. Revenue was 17,000 CNY for the quarter, matched by a gross profit of 17,000 CNY and a gross margin of roughly 100% on reported topline, but operating expenses dominated the P&L, driving an EBITDA of -37.95 million CNY and an operating loss of -41.43 million CNY. Net income came in at -38.20 million CNY with basic EPS of -0.26 CNY. The results underscore a heavy cash-burn narrative driven by R&D and G&A spend as the company advances its immuno-oncology pipeline, with little near-term revenue visibility.

Liquidity metrics appear supportive in the near term, with a current ratio of 6.59 and a cash ratio of 2.31, suggesting ample short-term liquidity relative to current liabilities. However, the enterprise value is negative (-16.37), indicating the market’s heavy discount on the operating cash burn while evaluating Sunho primarily as a cash-rich venture with substantial clinical risk. The balance sheet shows modest indebtedness (debt ratio 0.122; debt-to-capitalization 0.124) and cash per share of 2.92, which provides runway for pipeline development but does not offset the magnitude of the burn absent material revenue inflection or strategic partnerships.

Quarterly trajectory indicates Q2 2025 revenue of 17,000 CNY, up from 8,500 CNY in Q1 2025, suggesting a QoQ uptick in topline. Nonetheless, profitability remains elusive in the near term given ongoing R&D intensity and G&A. With no forward guidance provided in the disclosed materials, investors should anchor expectations to upcoming trial milestones, potential partnership announcements, and any capital-raising activity that could extend the cash runway. Progress in Phase II trials for IAH0968 and the status of IAP0971/IAE0972 will be critical to long-run value realization.